2nd Quarter - Report

COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) for COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC)

Firm
Client
Income
—
Expenses
$50,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company

LobbyistCovered position, as disclosed
GREGORY ARONIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 289 (114th), H.R. 1537 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.